Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.51 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 13/20 | 0.46 |
| ▸ | CA2 | P00918 | 13/20 | 0.46 |
| ▸ | CA9 | Q16790 | 13/20 | 0.46 |
| ▸ | CA4 | P22748 | 7/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3109555 | 0.80 | PTGS2 (0.43) | PTGS2PTGS1GRIA2CYP1A2CYP2D6 | |
| SCHEMBL3106235 | 0.80 | GRIA2 (0.53) | PTGS2PTGS1GRIA2CYP1A2CYP2D6 | |
| SCHEMBL10479634 | 0.80 | PTGS2 (0.43) | PTGS2PTGS1GRIA2CYP1A2CYP2D6 | |
| SCHEMBL10479605 | 0.80 | PTGS2 (0.59) | PTGS2PTGS1GRIA2CYP1A2CYP2D6 | |
| SCHEMBL10479643 | 0.80 | GRIA2 (0.44) | PTGS2PTGS1GRIA2CYP1A2CYP2D6 | |
| SCHEMBL10479389 | 0.80 | MAPT (0.49) | PTGS2GRIA2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL10479802 | 0.79 | PTGS2 (0.59) | PTGS2PTGS1GRIA2CYP1A2CYP2C9 | |
| SCHEMBL9148169 | 0.79 | PTGS2 (0.45) | PTGS2PTGS1GRIA2CYP1A2CYP2D6 | |
| SCHEMBL10479454 | 0.77 | MAPT (0.49) | PTGS2GRIA2CA1CA2CA9 | |
| SCHEMBL3107408 | 0.77 | GRIA2 (0.77) | PTGS2PTGS1GRIA2CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | CA2, CA7, CA9 | PTGS2 47/4885PTGS1 44/4885GRIA2 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.